Compare Interactive Brokers Group Inc. Class A Common Stock (IBKR) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Interactive Brokers Group Inc. Class A Common Stock vs Repligen Corporation Common Stock — how do they compare? Interactive Brokers Group Inc. Class A Common Stock trades at $83.84 (market cap $38.14B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Interactive Brokers Group Inc. Class A Common Stock is far larger — about 3.4× Repligen Corporation Common Stock's market cap, and Interactive Brokers Group Inc. Class A Common Stock pays a 0.42% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Interactive Brokers Group Inc. Class A Common Stock for 6 Days and Repligen Corporation Common Stock for 0 Days on average.
| IBKR | RGEN | |
|---|---|---|
Market Cap | $38.14B | $11.31B |
Volume | 4,556,837 | 1,216,919 |
Sector | Financials | Health |
52-Week High | $98.19 | $194.57 |
52-Week Low | $61.05 | $102.87 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $30.44B | $11.20B |
Dividend Yield | 0.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Interactive Brokers (IBKR) trades at $87.49, down 0.46% on the day, with technical indicators showing a bearish bias despite neutral oscillators. The company demonstrates strong fundamentals with revenue growth from $10.22B in 2025 to $11.1B projected for 2026, and net income rising from $984M to $1.1B. Recent earnings beats and expansion into cryptocurrency staking highlight ongoing business development, though valuation multiples appear elevated with a P/E of 34.72.
The outlook remains cautiously optimistic given analyst consensus pointing to 21% upside to the $106.11 price target, balanced by near-term technical weakness and stretched valuations. Key risks include competitive pressures in fintech and market volatility impacting trading volumes, while institutional sentiment shows mixed but generally positive positioning with 47% buy ratings.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Interactive Brokers Group Inc. Class A Common Stock
Interactive Brokers operates an electronic brokerage platform for trading stocks, options, futures, currencies, and other assets. It also provides clearing and custody services.
Read more on IBKR →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
